Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 326

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 13
Chunk 326
---
 Executive Officer)     /s/ Su-Leng Tan Lee Dated: April 15, 2025Su-Leng Tan Lee  Acting Chief Financial Officer  (Principal Financial and Accounting Officer)  

/s/ Chee Keong Yap Dated: April 15, 2025Chee Keong Yap  Director     /s/ Jook Yuen Low Dated: April 15, 2025Jook Yuen Low  Director  

/s/ Muhammad Azrul bin Abdul Hamid Dated: April 15, 2025Muhammad Azrul bin Abdul Hamid  Director  

 60Table of Contents

PART I FINANCIAL INFORMATION  Page    ITEM FINANCIAL STATEMENTS:   1.     Report of Independent Registered Public Accounting Firm F-2-F-3  Consolidated Balance Sheets as of December 31, 2024 and 2023F-4 to F-5  Consolidated Statements of Operations and Comprehensive Income/(Loss) for the Year Ended December 31, 2024 and 2023F-6  Consolidated Statements of Changes in Stockholders’ Equity for the Year Ended December 31, 2024 and 2023F-7  Consolidated Statements of Cash Flows for the Year Ended December 31, 2024 and 2023F-8 to F-9  Notes to the Consolidated Financial Statements F-10 to F-30 

 F-1Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders of 

BioNexus Gene Lab Corp.

Unit A-28-7, Level 28, Tower A

Menara UOA Bangsar

No. 5, Jalan Bangsar Utama 1

59000 Kuala Lumpur

Malaysia

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of BioNexus Gene Lab Corp. and subsidiaries (the Company) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income/(loss), consolidated statements of changes in stockholders’ equity, and consolidated statements of cash flows for each of the years in the two-year period ended December 31, 2024 and 2023, and the related notes (collectively referred to as the “